Tandem Mobi Insulin Pump
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year.
Tandem is now the only company that offers people living with diabetes two insulin pump options that connect with both Dexcom G6 and Dexcom G7, providing more choice in how they manage their diabetes. Tandem’s #1-rated2 t:slim X2™ insulin pump was the first AID system to feature Dexcom G7 integration, as announced in late 2023.
Tandem will email all Tandem Mobi users in the United States over the coming weeks, when their software update is available, with instructions on how to add the new feature free of charge by remote software update. Tandem Mobi pumps pre-loaded with the updated software are now shipping to new customers.
“Choice is a hallmark of our offerings, and we’ve proven this commitment with the expansion of our insulin pump portfolio and extended CGM compatibilities,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “With this integration, we’re providing more flexibility for our customers and continuing our decade-long partnership with Dexcom to bring innovative and discrete solutions to people living with diabetes.”
Tandem Mobi is small enough to be worn almost anywhere3, including a coin pocket, providing users with more discretion, comfort, and options for how they manage their diabetes. Powered by Control-IQ technology, which has demonstrated in real-world studies improved time in range overnight and during the day4, Tandem Mobi connects with Dexcom G7 or Dexcom G6 to predict glucose levels 30 minutes in advance and automatically adjusts insulin, if needed, to help prevent highs and lows.
With the integration of Dexcom G7, Tandem Mobi users can also experience:
- More time in closed loop with Dexcom G7’s 30-minute sensor warm-up time – faster than any other CGM on the market.5
- Additional discretion with Dexcom G7’s low-profile, all-in-one wearable.
“As the leader in connectivity, Dexcom has been the CGM of choice for the development of AID systems for over a decade,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “We are proud to offer people with diabetes the ability to use Dexcom G7, our smallest and most accurate CGM, with Tandem Mobi to create a seamless user experience.”
For more information about Tandem Mobi and how to start the order process, please visit www.tandemdiabetes.com/mobi.
- As of May, 2024. Data on file, Tandem Diabetes Care.
- dQ&A Q1 2024 US Diabetes Patient Voice Report.
- The pump should not be placed more than 12 inches (30.5 cm) above the infusion site. Doing so may result in over delivery of insulin.
- All published clinical trials and real-world studies of Control-IQ technology to date are based on use of Dexcom G6 CGM with the Tandem t:slim X2 insulin pump.
- Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
